来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 11-13 16:08:17

6.760

-0.115

-1.67%

最高6.950	最低6.660	成交量85.65万
今开6.850	昨收6.875	日振幅4.22%
总市值30.56亿	流通市值30.56亿	总股本4.52亿
成交额582.64万	换手率0.19%	流通股本4.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":6.76,"timestamp":1794557297004,"preClose":6.875,"halted":0,"volume":856500,"delay":0,"changeRate":-0.016727272727272757,"floatShares":451999999,"shares":451999999,"eps":-0.59,"marketStatus":"休市中","change":-0.115,"latestTime":"11-13 16:08:17","open":6.85,"high":6.95,"low":6.66,"amount":5826400,"amplitude":0.042182,"askPrice":6.785,"askSize":500,"bidPrice":6.76,"bidSize":11500,"shortable":3,"etf":0,"ttmEps":-0.26,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1687968000000,"exchange":"SEHK","adjPreClose":6.875,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":0.6644685803051119,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105","defaultTab":"news","newsList":[{"id":"2682532744","title":"港股异动 | 来凯医药-B(02105.HK)早盘涨超6% LAE124的临床前研究已入选2026美国肥胖周","url":"https://stock-news.laohu8.com/highlight/detail?id=2682532744","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682532744?lang=zh_cn&edition=full","pubTime":"2026-11-12 11:08","pubTimestamp":1794452883,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682353971","title":"代谢赛道下一个风口，来凯医药(02105)全线卡位","url":"https://stock-news.laohu8.com/highlight/detail?id=2682353971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682353971?lang=zh_cn&edition=full","pubTime":"2026-11-10 08:40","pubTimestamp":1794271210,"startTime":"0","endTime":"0","summary":"在ActRII这一新兴领域，中国创新药企延续了在多个创新药细分领域形成的竞争优势，其中港股上市的来凯医药，更是在这个细分赛道做出了世界级的深度，取得了研发进度和管线布局上的领先。LAE103崭露头角2026年11月9日，来凯医药发布公告宣布，旗下靶向ActRIIB的单克隆抗体LAE103，已经在澳大利亚完成针对超重或肥胖受试者的I期单剂量递增研究。ActRII赛道的全面布局LAE103的积极进展，也进一步凸显了来凯医药在ActRII赛道全面布局、协同推进的竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682874662","title":"来凯医药-B(02105)盘中涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682874662","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682874662?lang=zh_cn&edition=full","pubTime":"2026-11-09 14:32","pubTimestamp":1794205920,"startTime":"0","endTime":"0","summary":"11月9日，来凯医药-B盘中涨超8%，截至发稿，涨7.85%，报6.525港元，成交额306万港元。消息面上，来凯医药-B于11月9日发布公告，公司已在澳大利亚完成LAE103（ActRIIB单克隆抗体）在超重或肥胖受试者中的I期单剂量递增研究。研究结果显示，LAE103单次皮下给药的耐受性和安全性良好，未报告任何严重不良事件，无因不良事件而终止给药的情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611093926198697.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611093926198697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682824290","title":"来凯医药-B(02105)：LAE103在超重或肥胖受试者中的I期SAD研究成功完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2682824290","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682824290?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:25","pubTimestamp":1794183956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，本集团已在澳大利亚成功完成了LAE103在超重或肥胖受试者中的I期单剂量递增研究。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103在超重或肥胖受试者中的安全性、耐受性、药代动力学及药效学特性。LAE103单次皮下给药耐受性、安全性良好，未报告任何严重不良事件，亦无因不良事件而终止给药的报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"来凯医药-B(02105)：LAE103在超重或肥胖受试者中的I期SAD研究成功完成","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128849477","title":"来凯医药-B(02105)完成LAE103单剂量递增I期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1128849477","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128849477?lang=zh_cn&edition=full","pubTime":"2026-11-09 08:15","pubTimestamp":1794183326,"startTime":"0","endTime":"0","summary":"2026年11月9日，来凯医药有限公司-B公告称，集团已在澳大利亚完成LAE103在超重或肥胖受试者中的I期单剂量递增研究。公告显示，LAE103单次皮下给药耐受性和安全性良好，未出现任何严重不良事件，也无受试者因不良事件而终止给药。LAE103正被开发用于治疗肌少症性肥胖症及其他肌肉相关疾病。公司提醒，LAE103最终不一定能够成功开发及商业化，投资者需审慎行事。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147765854","title":"来凯医药-B更新10月股份变动月报表，股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147765854","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147765854?lang=zh_cn&edition=full","pubTime":"2026-11-05 16:43","pubTimestamp":1793868192,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年11月5日披露截至2026年10月31日的股份变动月报表。报告期内，公司法定及注册股本、已发行股份数量均无增减，整体股本维持不变。截至本月末，未有因上述各类激励计划产生的新股发行或库藏股变动，公司因此未获得行使期权相关的资金收入。公司表示，上述股份变动已获董事会批准，并严格遵守香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675392189","title":"港股异动 | 来凯医药-B(02105)涨超5% 已完成LAE102为期24周单药治疗研究低剂量组别治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675392189","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675392189?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:18","pubTimestamp":1791947911,"startTime":"0","endTime":"0","summary":"消息面上，10月13日，来凯医药-B发布公告，本集团已完成LAE102为期24周单药治疗研究低剂量组别的治疗。该数据与LAE102此前的单剂量递增及多剂量递增研究结果一致，显示出身体成分的积极变化。为期24周的治疗耐受性良好，未报告任何严重不良事件，亦无腹泻、肌肉痉挛或痤疮等报告，与先前披露的SAD及MAD研究结果一致。LAE102高浓度制剂近期已就绪，本集团已完成高剂量组别的受试者入组，以进一步评估LAE102在24周治疗期内高剂量水平下的疗效及安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02105","BK1161","VXUS","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675132392","title":"港股异动 | 来凯医药-B(02105.HK)涨超5% 已完成LAE102为期24周单药治疗研究低剂量组别治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675132392","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675132392?lang=zh_cn&edition=full","pubTime":"2026-10-14 11:18","pubTimestamp":1791947911,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191820006","title":"来凯医药-B（02105）完成LAE102低剂量24周单药研究并启动高剂量组入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1191820006","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191820006?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:15","pubTimestamp":1791850559,"startTime":"0","endTime":"0","summary":"2026年10月13日，来凯医药-B发布自愿公告称，公司已完成LAE102为期24周的低剂量单药治疗研究。结果显示，该组别在体重管理方面取得“令人鼓舞”的减重效果，并观察到肌肉增加与脂肪减少的积极体成分变化。公司表示，LAE102高浓度制剂已准备就绪，已完成高剂量组受试者入组，拟在同样的24周治疗期内进一步评估其疗效与安全性。公司提示，LAE102最终可能无法实现成功开发及商业化，提醒股东及潜在投资者交易公司证券时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675850923","title":"来凯医药-B(02105.HK)已完成LAE102为期24周单药治疗研究低剂量组别的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2675850923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675850923?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:13","pubTimestamp":1791850403,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153198524","title":"来凯医药-B更新2026年9月股份变动月报 新增发行2,730,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1153198524","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153198524?lang=zh_cn&edition=full","pubTime":"2026-10-07 16:36","pubTimestamp":1791362198,"startTime":"0","endTime":"0","summary":"来凯医药有限公司于2026年10月7日公布了截至2026年9月30日的证券变动月报表。报告期内，公司法定/注册股本总额维持50,000美元不变，注册资本中普通股数量依然为5,000,000,000股，面值0.00001美元/股。在已发行股份方面，截至2026年8月末，来凯医药-B已发行普通股449,331,350股，报告期内新增发行2,730,000股，期末已发行股份总数上升至452,061,350股。本月通过2024年6月14日采纳的2024年股份奖励计划增发2,730,000股普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671225842","title":"港股异动 | 来凯医药-B(02105)早盘涨超21% LAE118的I期临床研究近期完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2671225842","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671225842?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:30","pubTimestamp":1790739024,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B早盘涨超21%。截至发稿，涨18.33%，报7.585港元，成交额3283.41万港元。消息面上，来凯医药近日宣布，其自主研发的LAE118针对晚期实体瘤的I期临床研究受试者招募工作正在中国展开，首例入组已完成。此次临床研究主要评估LAE118单药及联合用药的安全性、耐受性、药代动力学和初步疗效，据悉，LAE118已获得中美两国新药临床试验申请批准，进入I期临床研究阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK4585","KCAI","BK1161","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183625312","title":"来凯医药-B2026年中期营收1.50亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183625312","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183625312?lang=zh_cn&edition=full","pubTime":"2026-09-18 22:58","pubTimestamp":1789743481,"startTime":"0","endTime":"0","summary":"来凯医药-B在2026年上半年实现营收1.50亿元。上年同期尚未体现相关收入，本期主要得益于外部授权交易及研发服务。公告显示，本期毛利达1.29亿元，毛利率约为86.1%。研发费用为0.97亿元，相较上年同期的1.05亿元下降了7.8%，主要系部分前期处于IND支持性阶段的候选药物于期内获得批准并已转入临床阶段，发现研究开支相应降低。管理费用为0.59亿元，相比上年同期的0.42亿元增长了38.5%，主要因以股份为基础的付款支出增加等因素所致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B2026年中期营收1.50亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665202703","title":"来凯医药-B(02105)合共发行27.3万股以满足根据2024年股份奖励计划授予的RSU的归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2665202703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665202703?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869922,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B(02105)发布公告，于2026年9月8日，该公司合共发行27.3万股普通股以满足根据2024年股份奖励计划授予的RSU的归属。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155209452","title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","url":"https://stock-news.laohu8.com/highlight/detail?id=1155209452","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155209452?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:16","pubTimestamp":1788869764,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）于2026年9月8日公告，因根据2024年股份奖励计划向公司董事及其他参与人授予的限制性股票单位（RSU）归属，公司于当日分别发行1,125,000股和1,605,000股普通股，合计发行2,730,000股。\n本次发行股份占公告前公司已发行股本449,331,350股的约0.2504%及0.3572%，发行价格均为每股0港元。发行完成后，公司已发行股本增至452,061,350股，库藏股仍为0股。\n公司董事会已对本次股份发行进行正式授权，并确认本次发行依据相关上市规则及适用法律规定进行，相关董事会决议及手续已履行。公告由公司秘书柯晨煜签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"来凯医药-B：9月8日发行2,730,000股新股，已发行股本增至452,061,350股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149410627","title":"来凯医药-B更新8月股份变动月报表 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1149410627","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149410627?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:12","pubTimestamp":1788513125,"startTime":"0","endTime":"0","summary":"来凯医药-B于2026年9月4日发布截至2026年8月31日的股份变动月报表。公告显示，公司当月注册股本及已发行股份均未发生变化，股本结构保持稳定。报告期末，公司已发行股份总数为449,331,350股，较上月底无任何增减调整。公告称，截至2026年8月末，公司就所发行的股份，已充分满足香港联交所主板上市规则所要求的公众持股量规定，并确认所有新增或变动均符合相关法规与上市要求，且获得董事会正式授权。公告由公司秘书柯晨煜签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664229418","title":"港股异动 | 来凯医药-B(02105.HK)尾盘涨超7% LAE118 I期临床完成首例受试者入组 许可协议最高5.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664229418","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664229418?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:34","pubTimestamp":1788420853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882311","title":"港股异动 | 来凯医药-B(02105)早盘涨超9% LAE118的I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882311?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:46","pubTimestamp":1788227194,"startTime":"0","endTime":"0","summary":"消息面上，9月1日，来凯医药-B发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额外对价的情况下，获得Vasque Bio已发行普通股最高达高双位数百分比的股权，或替代该等普通股的现金付款。如Vasque Bio达成符合特定条件的合资格战略合作或收购交易，集团将有权获得额外付款，金额最高可达该战略交易价值的50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK4588","BK1161","KCAI","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889447","title":"来凯医药-B(02105)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889447","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889447?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已于中国启动LAE118用于治疗晚期实体瘤的I期临床研究的受试者招募，且已完成首例受试者入组。集团亦有权在无需额 外 对 价 的 情 况 下 ， 获 得 Vasque Bio 已 发 行 普 通 股 最 高 达 高 双 位 数 百 分 比 的 股权，或替代该等普通股的现金付款。Vasque Bio主要专注于罕见疾病治疗药物的开发，集团则专注于在许可区域以外开 发LAE118 的肿瘤 疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02105"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664889441","title":"来凯医药-B(02105.HK)：LAE118(一种新型的PI3Kα泛突变选择性抑制剂) I期临床研究首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2664889441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664889441?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:19","pubTimestamp":1788221941,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02105","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":0.1174},{"period":"1month","weight":-0.0066},{"period":"3month","weight":-0.0343},{"period":"6month","weight":-0.5445},{"period":"1year","weight":-0.4348},{"period":"ytd","weight":-0.5018}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症、肝脏疾病及肥胖症创新疗法的发现、开发及商业化的投资控股公司。该公司尚处于研发阶段。该公司的在研管线产品包括Afuresertib（LAE002）、LAE001、LAE109、LAE111、LAE112、LAE113、LAE117、LAE118、LAE119、LAE102、LAE103、LAE104、LAE105、LAE106、LAE107、LAE120、LAE123等。Afuresertib是一种三磷酸腺苷（ATP）竞争性AKT抑制剂。LAE001是雄激素合成抑制剂，可同时抑制CYP17A1及CYP11B2。该公司主要在中国、美国、欧洲、韩国等市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.264392},{"month":2,"riseRate":0.666667,"avgChangeRate":0.234103},{"month":3,"riseRate":0.666667,"avgChangeRate":0.090739},{"month":4,"riseRate":0.333333,"avgChangeRate":0.001974},{"month":5,"riseRate":0.666667,"avgChangeRate":0.062052},{"month":6,"riseRate":0,"avgChangeRate":-0.226423},{"month":7,"riseRate":0.25,"avgChangeRate":-0.072516},{"month":8,"riseRate":0.75,"avgChangeRate":0.06659},{"month":9,"riseRate":0.75,"avgChangeRate":0.102989},{"month":10,"riseRate":0.5,"avgChangeRate":0.000639},{"month":11,"riseRate":1,"avgChangeRate":0.352707},{"month":12,"riseRate":0,"avgChangeRate":-0.176326}],"exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}